Cargando…

Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

BACKGROUND: GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivalent influenza vaccine (IIV4) to harmonize the process among different strains, resulting in an increased number of finished vaccine doses, while compensating for the change from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Claeys, Carine, Drame, Mamadou, García-Sicilia, José, Zaman, Khalequ, Carmona, Alfonso, Tran, Phu My, Miranda, Mariano, Martinón-Torres, Federico, Thollot, Franck, Horn, Michael, Schwarz, Tino F., Behre, Ulrich, Merino, José M., Sadowska-Krawczenko, Iwona, Szymański, Henryk, Schu, Peter, Neumeier, Elisabeth, Li, Ping, Jain, Varsha K., Innis, Bruce L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907359/ https://www.ncbi.nlm.nih.gov/pubmed/29669531 http://dx.doi.org/10.1186/s12879-018-3079-8

Ejemplares similares

Quadrivalent Influenza Vaccine Prevents Illness and Reduces Healthcare Utilization Across Diverse Geographic Regions During Five Influenza Seasons: A Randomized Clinical Trial
por: Dbaibo, Ghassan, et al.
Publicado: (2020)

Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children
por: Claeys, Carine, et al.
Publicado: (2019)

A Randomized Trial of Candidate Inactivated Quadrivalent Influenza Vaccine versus Trivalent Influenza Vaccines in Children Aged 3–17 Years
por: Domachowske, Joseph B., et al.
Publicado: (2013)

A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control
por: Ray, Riju, et al.
Publicado: (2017)

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
por: Kieninger, Dorothee, et al.
Publicado: (2013)

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine Candidate: A Phase III Randomized Controlled Trial in Children
por: Langley, Joanne M., et al.
Publicado: (2013)

A historically-controlled Phase III study in adults to characterize the acceptability of a process change for manufacturing inactivated quadrivalent influenza vaccine
por: Jain, Varsha K, et al.
Publicado: (2014)

Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial
por: Pepin, Stephanie, et al.
Publicado: (2021)

Immunogenicity and Safety of an EB66 Cell-Culture-Derived Influenza A/Indonesia/5/2005(H5N1) AS03-Adjuvanted Vaccine: A Phase 1 Randomized Trial
por: Schuind, Anne, et al.
Publicado: (2015)

Healthcare-associated infections in a neonatal intensive care unit
por: Sadowska-Krawczenko, Iwona, et al.
Publicado: (2012)

Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial
por: Wang, Long, et al.
Publicado: (2016)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
por: Knuf, Markus, et al.
Publicado: (2022)

Post-Marketing Surveillance Observational Study of Quadrivalent Meningococcal Diphtheria Toxoid Conjugate Vaccine (MenACWY-DT, MCV4/Menactra(®)) in the Republic of Korea, 2014–2019
por: Kim, Hee Soo, et al.
Publicado: (2021)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Evaluation of Methods to Minimize Pain in Newborns during Capillary Blood Sampling for Screening: A Randomized Clinical Trial
por: Napiórkowska-Orkisz, Magdalena, et al.
Publicado: (2022)

Safety and immunogenicity of an intramuscular quadrivalent influenza vaccine in children 3 to 8 y of age: A phase III randomized controlled study
por: Pepin, Stephanie, et al.
Publicado: (2016)

From trivalent to quadrivalent influenza vaccines: Public health and economic burden for different immunization strategies in Spain
por: Crépey, Pascal, et al.
Publicado: (2020)

Immunogenicity and safety of Southern Hemisphere inactivated quadrivalent influenza vaccine: a Phase III, open-label study of adults in Brazil
por: Zerbini, Cristiano A.F., et al.
Publicado: (2016)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial
por: Jain, Varsha K., et al.
Publicado: (2017)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2017)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
por: van der Vliet, D., et al.
Publicado: (2021)

Association Between Hemagglutination Inhibition Antibody Titers and Protection Against Reverse-Transcription Polymerase Chain Reaction–Confirmed Influenza Illness in Children 6–35 Months of Age: Statistical Evaluation of a Correlate of Protection
por: Danier, Jasur, et al.
Publicado: (2021)

Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season
por: Ganczak, Maria, et al.
Publicado: (2019)

An assessment of prime‐boost vaccination schedules with AS03(A)‐adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults
por: Gillard, Paul, et al.
Publicado: (2012)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany
por: Kohli, Michele A., et al.
Publicado: (2022)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012–2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial
por: Langley, Joanne M., et al.
Publicado: (2015)

Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial
por: Sesay, Sanie, et al.
Publicado: (2017)

Correction: Modelling the effects of quadrivalent Human Papillomavirus (HPV) vaccination in Puerto Rico
por: Ortiz, Ana Patricia, et al.
Publicado: (2018)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

The Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Indonesia
por: Kosen, Soewarta, et al.
Publicado: (2017)

Ongoing inadequacy of quadrivalent HPV vaccine safety studies
por: Little, Deirdre T, et al.
Publicado: (2020)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_um3ljrkfffq40g21tkvlbaiu5b